Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies

Project Information

ExitAplasia

Grant agreement ID: 827629

DOI

10.3030/827629

Project closed

EC signature date 9 August 2018

Start date 1 November 2018

End date 30 April 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

REGSTEM
France

Periodic Reporting for period 1 - ExitAplasia (Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies)

Reporting period: 2018-11-01 to 2019-04-30

Summary of the context and overall objectives of the project

Some cancers, like leukaemia or cancers of some solid organs, need particularly aggressive treatments: heavy chemotherapy, alone or associated with radiotherapy (total body irradiation).
These treatments induce “aplasia”: the bone marrow doesn’t produce cells for the bloodstream anymore; these cells are well known and crucial for life: red cells (oxygen transport), white cells (immune defense against infection, bacteria, viruses), and platelets (to prevent bleeding after injuries).
These patients can be very young and even child can be concerned.
This aplasia has to be transient: it is a very serious condition which leads to death if it lasts too long; after a few days, the patients usually recover from aplasia, but meanwhile, they can suffer from uncontrolled infection or life-threatening bleeding.
Thus, the longer is aplasia, the higher is the risk of death for the patients. And the patients who do not succeed in recover from aplasia die.

We invented a mean to shorten this aplasia, increase the rate and speed of recovery from it. We are currently designing new drugs to specifically shorten it and increase the chance of survival for these patients.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

We designed new chemical molecules and synthesize them ; we did some preliminary experiments in laboratory to check that they could be good candidates for future efficient medicines for patients.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

We expect to find a new molecule that could become a marketed drug for patients who suffer from aplasia. This would save patients, which is obviously our primary goal.
It would also strongly shorten the lenght and consistenly decrease the cost of hospitalization. Thus, the financial burden of the concerned diseases would also be significantly decreased.

Illustration of kind of patient concerned (actress !)